Flanagan W. Michael Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
10
Insider Sells Sum
$11.42M

Insider Activity of Flanagan W. Michael

According to the SEC Form 4 filings, Flanagan W. Michael, being in a position of

  1. Chief Scientific Officer at Atrium Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 8907 shares for $644,790,
    over all time since 2024-01-22, has bought 0 shares, and sold 336230 shares for $13.5M.

Biography of Flanagan W. Michael

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$644,7902100

Comparison of Insiders on Amount of Buys and Sells

2026-01-21SaleAvidity Biosciences, Inc.
RNA
Chief Scientific Officer
6,534
0.0043%
$72.45$473,388
2026-01-07SaleAvidity Biosciences, Inc.
RNA
Chief Scientific Officer
2,373
0.0018%
$72.23$171,402
2025-09-11SaleAvidity Biosciences, Inc.
RNA
Chief Scientific Officer
20,000
0.0147%
$38.94$778,702
2025-06-11SaleAvidity Biosciences, Inc.
RNA
Chief Scientific Officer
20,000
0.017%
$32.88$657,694
2025-03-20SaleAvidity Biosciences, Inc.
RNA
Chief Scientific Officer
11,780
0.0099%
$31.06$365,868
2025-03-11SaleAvidity Biosciences, Inc.
RNA
Chief Scientific Officer
20,000
0.0169%
$30.13$602,614
2025-01-21SaleAvidity Biosciences, Inc.
RNA
Chief Scientific Officer
5,672
0.0044%
$28.60$162,192
2024-12-18SaleAvidity Biosciences, Inc.
RNA
CSTO
12,742
0.0113%
$32.66$416,154
2024-12-11SaleAvidity Biosciences, Inc.
RNA
CSTO
24,000
0.0201%
$35.77$858,401
2024-10-01SaleAvidity Biosciences, Inc.
RNA
CSTO
62,500
0.058%
$47.62$2.98M
2024-09-23SaleAvidity Biosciences, Inc.
RNA
CSTO
25,000
0.0214%
$43.95$1.1M
2024-09-11SaleAvidity Biosciences, Inc.
RNA
CSTO
111,394
0.0877%
$40.40$4.5M
2024-06-18SaleAvidity Biosciences, Inc.
RNA
CSTO
10,106
0.0077%
$39.13$395,445
2024-01-22SaleAvidity Biosciences, Inc.
RNA
CSTO
4,129
0.0008%
$10.13$41,827
Total: 14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.